Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy

Table 3

Number of cases, person-years, and rates per 100 person-years with 95% CI of hypoglycemia (overall and stratified by the previous episode of hypoglycemia) and cardiovascular events in type 2 diabetes mellitus patients initiating NPH insulin or DPP-4, 2011–2013.

Group	Number of events	Time to event (years), median (IQR)	Time at risk (years)	Rate (per 100 person-years)	95% CI
Hypoglycemia (overall)
NPH	694	0.41 (0.25–0.77)	2430	28.6	26.5–30.8
DPP-4	2193	0.60 (0.33–1.19)	43,139	5.1	4.9–5.3
Hypoglycemia (with previous hypoglycemia episode)
NPH	441	0.27 (0.10–0.49)	301	146.4	133.3–160.7
DPP-4	620	0.37 (0.17–0.81)	1206	51.4	47.5–55.6
Hypoglycemia (without previous hypoglycemia episode)
NPH	253	0.48 (0.32–0.87)	2129	11.9	10.5–13.4
DPP-4	1573	0.61 (0.33–1.21)	41,933	3.8	3.6–3.9
Cardiovascular events
NPH	1014	0.49 (0.32–0.95)	43,867	2.31	2.17–2.46
DPP-4	69	0.60 (0.32–1.21)	2833	2.44	1.92–3.08

One year before cohort entry. IQR: interquartile range (Q1–Q3).